The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 811-817

  Tubert, Pere ^a,b   Rodríguez, Montserrat ^a,b   Ribó, Marc ^a,b   Benito, Antoni ^a,b   Vilanova, Maria ^a,b  

^a UNIVERSITY OF GIRONA   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

Author keywords

Antitumor drug; Cytotoxicity; Human pancreatic ribonuclease; Nuclear localization signal; Protein engineering

Indexed keywords

ENZYME INHIBITOR; NUCLEAR RNA; PANCREATIC RIBONUCLEASE; PANCREATIC RIBONUCLEASE PE5; RANPIRNASE; UNCLASSIFIED DRUG; AMINO ACID; MUTANT PROTEIN; RNA;

ARTICLE; CELL NUCLEUS; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME STABILITY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA CLEAVAGE; RNA DEGRADATION; THERMOSTABILITY; ACTIVE TRANSPORT; CELL DEATH; ENZYME SPECIFICITY; ENZYMOLOGY; HELA CELL; METABOLISM; TIME;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACIDS; CELL DEATH; CELL NUCLEUS; HELA CELLS; HUMANS; MUTANT PROTEINS; RIBONUCLEASE, PANCREATIC; RNA; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 84855396190     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9426-2     Document Type: Article

References (38)

1. Schein CH (1997) From housekeeper to microsurgeon: the diagnostic and therapeutic potential of ribonucleases. Nat Biotechnol 15:529-536
2. Newton DL, Ryback SM (2001) Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA. Expert Opin Biol Ther 1:995-1003
3. Schirrmann T, Krauss J, Arndt MA, Rybak SM, Dubel S (2009) Targeted therapeutic RNases (ImmunoRNases). Expert Opin Biol Ther 9:79-95
4. Pavlakis N, Vogelzang NJ (2006) Ranpirnase-an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 6:391-399
5. Benito A, Ribo M, Vilanova M (2005) On the track of antitumour ribonucleases. Mol Biosyst 1:294-302
6. De Lorenzo C, Di Malta C, Cali G, Troise F, Nitsch L, D'Alessio G (2007) Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. FEBS Lett 581:296-300
7. Leland PA, Schultz LW, Kim BM, Raines RT (1998) Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci USA 95:10407-10412
8. Piccoli R et al (1999) A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells. Proc Natl Acad Sci USA 96:7768-7773
9. Vicentini AM, Kieffer B, Matthies R, Meyhack B, Hemmings BA, Stone SR, Hofsteenge J (1990) Protein chemical and kinetic characterization of recombinant porcine ribonuclease inhibitor expressed in Saccharomyces cerevisiae. Biochemistry 29:8827-8834
10. Leland PA, Staniszewski KE, Kim BM, Raines RT (2001) Endowing human pancreatic ribonuclease with toxicity for cancer cells. J Biol Chem 276:43095-43102
11. Bosch M, Benito A, Ribo M, Puig T, Beaumelle B, Vilanova M (2004) A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity. Biochemistry 43:2167-2177
12. Roth JS, Juster H (1972) On the absence of ribonuclease inhibitor in rat liver nuclei. Biochim Biophys Acta 287:474-476
13. Rodriguez M, Benito A, Tubert P, Castro J, Ribo M, Beaumelle B, Vilanova M (2006) A cytotoxic ribonuclease variant with a discontinuous nuclear localization signal constituted by basic residues scattered over three areas of the molecule. J Mol Biol 360:548-557
14. Leland PA, Raines RT (2001) Cancer chemotherapy-ribonucleases to the rescue. Chem Biol 8:405-413
15. Boulanger C, Di Giorgio C, Vierling P (2005) Synthesis of acridinenuclear localization signal (NLS) conjugates and evaluation of their impact on lipoplex and polyplex-based transfection. Eur J Med Chem 40:1295-1306
16. Haefliger P, Agorastos N, Renard A, Giambonini-Brugnoli G, Marty C, Alberto R (2005) Cell uptake and radiotoxicity studies of an nuclear localization signal peptide-intercalator conjugate labeled with [99mTc (CO) 3]+. Bioconjug Chem 16:582-587
17. Chen P et al (2006) Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 1 11In in human myeloid leukemia cells. J Nucl Med 47:827-836
18. Leland PA, Staniszewski KE, Kim B, Raines RT (2000) A synapomorphic disulfide bond is critical for the conformational stability and cytotoxicity of an amphibian ribonuclease. FEBS Lett 477:203-207
19. Canals A, Ribo M, Benito A, Bosch M, Mombelli E, Vilanova M (1999) Production of engineered human pancreatic ribonucleases, solving expression and purification problems, and enhancing thermostability. Protein Expr Purif 17:169-181
20. Ribo M, Benito A, Canals A, Nogues MV, Cuchillo CM, Vilanova M (2001) Purification of engineered human pancreatic ribonuclease. Methods Enzymol 341:221-234
21. Ribo M, Bosch M, Torrent G, Benito A, Beaumelle B, Vilanova M (2004) Eur J Biochem 271:1163-1171
22. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4:2411-2423
23. Font J, Benito A, Torrent J, Lange R, Ribo M, Vilanova M (2006) Pressure-and temperature-induced unfolding studies: thermodynamics of core hydrophobicity and packing of ribonuclease A. Biol Chem 387:285-296
24. Boix E, Nogues MV, Schein CH, Benner SA, Cuchillo CM (1994) Reverse transphosphorylation by ribonuclease A needs an intact p2-binding site. Point mutations at Lys-7 and Arg-10 alter the catalytic properties of the enzyme. J Biol Chem 269:2529-2534
25. Leatherbarrow RJ, Fersht AR (1987) Investigation of transition-state stabilization by residues histidine-45 and threonine-40 in the tyrosyltRNA synthetase. Biochemistry 26:8524-8528
26. Mastronicola MR, Piccoli R, D'Alessio G (1995) Key extracellular and intracellular steps in the antitumor action of seminal ribonuclease. Eur J Biochem 230:242-249
27. Liao YD, Huang HC, Chan HJ, Kuo SJ (1996) Large-scale preparation of a ribonuclease from Rana catesbeiana (bullfrog) oocytes and characterization of its specific cytotoxic activity against tumor cells. Protein Expr Purif 7:194-202
28. Iordanov MS, Ryabinina OP, Wong J, Dinh TH, Newton DL, Rybak SM, Magun BE (2000) Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 60:1983-1994
29. Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K, Youle RJ (2002) Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem 277:15142-15146
30. Ardelt B, Ardelt W, Darzynkiewicz Z (2003) Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle 2:22-24
31. Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z (2008) The cytotoxic ribonuclease onconase targets RNA interference (siRNA). Cell Cycle 7:3258-3261
32. Mondino A, Jenkins MK (1995) Accumulation of sequencespecific RNA-binding proteins in the cytosol of activated T cells undergoing RNA degradation and apoptosis. J Biol Chem 270:26593-26601
33. Narayanan A, Lukowiak A, Jady BE, Dragon F, Kiss T, Terns RM, Terns MP (1999) Nucleolar localization signals of box H/ACA small nucleolar RNAs. EMBO J 18:5120-5130
34. Lukowiak AA, Narayanan A, Li ZH, Terns RM, Terns MP (2001) The snoRNA domain of vertebrate telomerase RNA functions to localize the RNA within the nucleus. RNA 7:1833-1844
35. Ardelt W, Shogen K, Darzynkiewicz Z (2008) Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes. Curr Pharm Biotechnol 9:215-225
36. Futami J, Maeda T, Kitazoe M, Nukui E, Tada H, Seno M, Kosaka M, Yamada H (2001) Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry 40:7518-7524
37. Makarov AA, Ilinskaya ON (2003) Cytotoxic ribonucleases: molecular weapons and their targets. FEBS Lett 540:15-20
38. Costanzi J, Sidransky D, Navon A, Goldsweig H (2005) Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest 23:643-650